Surgical Correction of Moderate Ischemic Mitral Regurgitation

Moderate Ischemic Mitral Regurgitation Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00394797
• Other study ID #: IMR001
• Status: Completed
• Phase: N/A
• First received: October 31, 2006
• Last updated: May 31, 2011

Study information

• Verified date: May 2011
• Source: Shaare Zedek Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to try and determine whether repair of moderate ischemic mitral regurgitation at the time of coronary bypass graft surgery (CABG) has an impact on survival.We will compare patients undergoing CABG + mitral repair or CABG only groups. Primary endpoints include late survival. Secondary endpoints include event free survival, symptoms, and echocardiographic outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients undergoing coronary bypass surgery who have moderate degree of ischemic MR

Exclusion Criteria:

• etiology of mitral regurgitation other than ischemic, degree of regurgitation other than moderate.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Mitral Valve Insufficiency
• Moderate Ischemic Mitral Regurgitation

Intervention

Procedure:
• mitral valve annuloplasty

Locations

Country	Name	City	State
Israel	Shaare Zedek Medical Center	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Shaare Zedek Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	survival at 1,5 and 10 years
Secondary	event free survival
Secondary	symptoms
Secondary	echocardiographic parameters